Genmab — Januar 2014
-
det er egentlig også mit gæt - men alligevel en adr handel til dkk 180k...
-
PCYC er nu steget 40% siden nyheden om RESONATE. Det er mere end GENs markedsværdi - er markedet ved at løbe amok på den aktie, eller hvad dælen sker der?
-
Lidt uddybende omkring artiklen om IgA http://embomolmed.embopress.org/content/embomm/5/8/1213.reviewer-comments.pdf
-
Ny medarbejder i Genmab har skrevet flg http://dspace.library.uu.nl/bitstream/handle/1874/286536/overdijk.pdf;jsessionid=AAC56CE9D06427C61745D50CB791EACC?sequence=2
-
-
Er det her godt, men skidt for GEN aktionærer ? http://jyllands-posten.dk/aarhus/ECE4465078/ny-opdagelse-kan-sla-kraeft-ihjel/
-
Den danske opdagelse handler om at bekæmpe blærekræft, men gruppen har gjort lignende fund inden for tyktarmskræft.
-
man målretter - dvs. sprøjter direkte ind i canceren dvs. det lyder typisk som forsøg mod solid tumors. Så ikke konkurrent til andet end Humax-TF-ADC pt. Men nu er det jo meeeeeeeeeeeeega early og mange mange mange år ude i fremtiden selv hvis det giver succes i klinikken også
-
Det er mere positivt for Exiqon fordi det sætter fokus på RNA forskning som de sælger reagenser til.
-
-
Interessant: Kvalitetsjournalistik kræver investeringer. Del venligst denne artikel med andre ved at bruge nedenstående link. http://medwatch.dk/Medicinal___Biotek/article6413398.ece?utm_source=Feed&utm_medium=top&utm_campaign=Morgen&utm_content=2014-01-20+08%3A13%3A00#ixzz2qvZb9XlE
Kopier og videresend ikke artiklen. Det er i strid med ophavsretsloven og vores abonnementsbetingelser: http://medwatch.dk/service/betingelserSamtidig mener Bruce Booth, at aktiviteterne og snakken på konferenc
-
JPM 2014: Broad Optimism About Biotech Innovation - LifeSciVC
The annual biotech pilgrimage to San Francisco has come to an end, and the upbeat, optimistic sentiment from #JPM14 bodes well as a barometer of the healthcare industry. Amidst the presentations and partying, there was lots of bullish thinking about
LifeSciVC (lifescivc.com)
-
-
We continue to believe
that the biotech industry is in the early innings of an innovation cycle with many labelexpansion
opportunities and novel agents in phase 2 or 3 trials that are largely
unaccounted for in Street models. Hence, we are bullish on the group for 2014.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind